The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The protections extend through at least 2035, with the potential for further extensions
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Subscribe To Our Newsletter & Stay Updated
